Metabolic syndrome, hepatic fibrosis, and steatosis diagnosed by liver stiffness measurement and controlled attenuation parameter after liver transplantation: the impact on long-term survival

Eshraghian, Ahad; Fattahi, Mohammad Reza; Taghavi, Alireza; Shamsaeefar, Alireza; Mansoorian, Mohsenreza; Kazemi, Kourosh; Nikeghbalian, Saman; Malekhosseini, Seyed Ali

doi:10.1080/17474124.2022.2137488

Cited by 6 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be explained by several factors. By definition, MS is associated with hepatic steatosis, which per se does not translate into an increased risk of post-transplant mortality [ 47 , 48 ]. Importantly, steatosis of the allograft can develop de novo or result from the recurrence of the underlying liver disease.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

De Novo Metabolic Syndrome 1 Year after Liver Transplantation and Its Association with Mid- and Long-Term Morbidity and Mortality in Liver Recipients

Czarnecka,

Tronina

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Metabolic syndrome (MS) constitutes an important source of cardiovascular- and cancer-related morbidity and mortality in the general population. Limited information is available on whether these findings can be directly extrapolated to liver recipients. This study aimed to investigate the impact of post-transplant MS present 1 year after liver transplantation on survival rates, risk of major cardiovascular events (CVEs), and de novo malignancies. Methods: Adult deceased-liver-donor recipients who underwent transplantation in our centre between 2010 and 2019 and reached at least 1 year of post-transplantation follow-up were eligible. Results: Of 259 enrolled patients, 20% developed post-transplant MS 1 year after the procedure. The presence of post-transplant MS at 1 year did not affect all-cause mortality (p = 0.144) and risk of de novo malignancies (p = 0.198) in liver recipients. However, it was associated with an overall and time-dependent increase in the risk of major CVEs (p < 0.001). MASH aetiology of liver disease, pre-existing major CVEs, and development of de novo malignancy were independent predictors of all-cause mortality in liver recipients. Conclusions: New onset MS exerts a wide-ranging effect on the post-transplant prognosis of liver recipients. Obtaining optimal control over all modifiable metabolic risk factors is central to improving long-term outcomes in this population.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Vallin et al also suggested that cases of recurrent MAFLD constitute an irreversible disease [ 49 ]. Accordingly, many studies point towards the recurrence of MASH and liver fibrosis as an important source of post-transplant deaths [ 47 ].…”

Section: Discussionmentioning

confidence: 99%